A Randomized, Double-blind, Multicenter, Active-Controlled Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Treatment-resistant Depression
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 19 Apr 2018
At a glance
- Drugs Esketamine (Primary) ; Duloxetine; Escitalopram; Sertraline; Venlafaxine
- Indications Depression; Major depressive disorder
- Focus Registrational; Therapeutic Use
- Acronyms SUSTAIN-1
- Sponsors Janssen Research & Development
- 18 Apr 2018 This study has been completed in Czech Republic (End date: 2018-02-15)
- 28 Mar 2018 This trial has been completed in Slovakia (End Date;2018-02-16).
- 15 Mar 2018 This trial has been completed in Belgium (End Date;2018-02-16).